Competition record
Zoetis
Deep profile · 0 linked library matters
Zoetis is the animal-health company spun from Pfizer, selling Apoquel and Cytopoint to vet clinics and vaccines and medicines to livestock producers. Elanco, Merck Animal Health, and Boehringer Ingelheim sell the alternatives.
Overview
Zoetis is based in Parsippany, New Jersey. In companion animal, Apoquel and Cytopoint treat allergic itch in dogs, Librela treats osteoarthritis pain, and Simparica Trio is a parasiticide sold through veterinary clinics.
Elanco, Merck Animal Health, and Boehringer Ingelheim Animal Health compete for the same clinic shelf and for the same cattle, swine, and poultry accounts. A clinic that starts a dog on Apoquel is hard to move, and a livestock integrator that qualifies a vaccine into a barn program does not change it mid-cycle.
Chewy and other online pharmacies have become a second channel for companion-animal prescriptions, which changes who captures the refill even when the veterinarian made the original recommendation. Livestock products still move through distributors and direct contracts with producers.
Competition footprint
Veterinary clinics are the gate for Apoquel, Cytopoint, and Simparica, and they choose a primary parasiticide.
Livestock integrators award vaccine and antibiotic programs that last a production cycle.
Online pet pharmacies can divert refills once a prescription can legally be filled outside the clinic.
Consumer & business angle
Dog owners refill a chronic itch drug wherever the veterinarian's prescription is honored.
A poultry or cattle producer that changes biologics mid-program risks the whole flock or herd protocol.
What to watch
- Clinic versus online-pharmacy share of companion-animal refills.
- Livestock tender awards against Elanco and Merck Animal Health, and any new monoclonal competing with Librela.
Markets
companion animal medicines · livestock animal health
Also known as: apoquel, cytopoint, simparica
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.